SA
Log In
ROIV
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
14 analysts·Moderate coverage
73
Score
13 Buy (93%)1 Hold (7%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1393%
Hold
17%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$30.00
+6.6%
Consensus
$32.00
+13.7%
Bull
$40.00
+42.2%
12-Month Target Range14 analysts
$30.00$32.00$40.00
Current $28.14Consensus
Current Price
$28.14
Upside to Consensus
$3.86

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+736.05%
EPS—
FY2028
Rev+558.43%
EPS—
FY2029
Rev+238.50%
EPS—

Earnings Surprises

Recent Analyst Actions

Apr 16, 2026Piper Sandler
Roivant Sciences assumed with an Overweight at Piper Sandler
Target:$40.00
+36.7%from $29.26
Mar 4, 2026H.C. Wainwright
Roivant Sciences (ROIV) PT Raised to $34 at H.C. Wainwright
Target:$34.00
+18.0%from $28.81
Feb 10, 2026H.C. Wainwright
Roivant Sciences price target raised to $33 from $26 at H.C. Wainwright
Target:$33.00
+19.3%from $27.67
Feb 9, 2026Jefferies
Roivant Sciences price target raised to $30 from $24 at Jefferies
Target:$30.00
+13.4%from $26.45
Feb 9, 2026Guggenheim
Roivant Sciences price target raised to $30 from $28 at Guggenheim
Target:$30.00
+16.2%from $25.82
Dec 18, 2025Guggenheim
Roivant Sciences price target raised to $28 from $25 at Guggenheim
Target:$28.00
+25.6%from $22.30
Dec 15, 2025Leerink Partners
Roivant Sciences (ROIV) PT Raised to $32 at Leerink Partners
Target:$32.00
+44.8%from $22.09
Dec 12, 2025H.C. Wainwright
Roivant Sciences price target raised to $26 from $23 at H.C. Wainwright
Target:$26.00
+21.1%from $21.46
Nov 14, 2025Guggenheim
Roivant Sciences (ROIV) PT Raised to $25 at Guggenheim
Target:$25.00
+21.6%from $20.56
Nov 11, 2025Leerink Partners
Roivant Sciences (ROIV) PT Raised to $29 at Leerink Partners
Target:$29.00
+37.0%from $21.17
Sep 18, 2025Jefferies
Roivant Sciences price target raised to $20 from $18 at Jefferies
Target:$20.00
+29.3%from $15.47
Sep 18, 2025Guggenheim
Roivant Sciences price target raised to $21 from $15 at Guggenheim
Target:$21.00
+37.8%from $15.24
Sep 18, 2025H.C. Wainwright
Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright
Target:$20.00
+31.2%from $15.24
Oct 21, 2024Leerink Partners
Leerink Partners Reiterates Outperform Rating on Roivant Sciences (ROIV)
Target:$17.00
+42.6%from $11.92
Sep 19, 2024Goldman Sachs
Goldman Sachs Reiterates Buy Rating on Roivant Sciences (ROIV)
Target:$17.00
+41.0%from $12.05
Sep 11, 2024Bank of America Securities
Roivant Sciences (ROIV) PT Raised to $12.50 at BofA Securities
Target:$12.50
+0.4%from $12.46
May 31, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Roivant Sciences (ROIV)
Target:$20.00
+92.5%from $10.39
Apr 3, 2024H.C. Wainwright
Roivant Sciences (ROIV) PT Raised to $18 at H.C. Wainwright, 'brepocitinib has blockbuster potential'
Target:$18.00
+64.8%from $10.92
Apr 3, 2024Deutsche Bank
Roivant Sciences price target raised to $15 from $14 at Deutsche Bank
Target:$15.00
+37.4%from $10.92
Apr 2, 2024Goldman Sachs
Roivant Sciences (ROIV) PT Raised to $18 at Goldman Sachs
Target:$18.00
+64.8%from $10.92
Mar 13, 2024Goldman Sachs
Roivant Sciences (ROIV) PT Raised to $16 at Goldman Sachs
Target:$16.00
+50.7%from $10.62
Jan 5, 2023Citigroup
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $14
Target:$14.00
+85.2%from $7.56
Dec 19, 2022Leerink Partners
SVB Leerink Maintains Outperform on Roivant Sciences, Raises Price Target to $10
Target:$10.00
+36.6%from $7.32
Aug 18, 2022Citigroup
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $10
Target:$10.00
+147.5%from $4.04
May 24, 2022Goldman Sachs
Goldman Sachs Maintains Buy on Roivant Sciences, Lowers Price Target to $12
Target:$12.00
+210.9%from $3.86

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance